Phase 1CompletedINTERVENTIONAL
A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years
ClinicalTrials.gov · NCT01789086 · Registry updated: 2016-12-22
- Condition / research focus
- Metabolism and Nutrition Disorder; Obesity
- Sponsor
- Novo Nordisk A/S
- Countries with listed sites
- Germany
- Registry dates and results
- Start: 2013-02. Completion: 2014-05 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- liraglutide (drug)
- placebo (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Novo Nordisk Investigational Site
Hanover, Germany
Site recruitment: Not reported